ArticleBiochemistry2026
Substrate Specificity and Kinetic Mechanism of the NAD+-Dependent Deacylase from Mycobacterium tuberculosis, Rv1151c (Mt-Sirt).
Article in Biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The pathogen Mycobacterium tuberculosis (Mtb) relies on extensive metabolic remodeling and post-translational regulation of its proteins to retain persistence in its host, yet these biochemical functions remain largely uncharacterized, including the actions of lysine deacylases. Here, we characterized Rv1151c, the sole annotated NAD+-dependent deacylase in Mtb, which we designate Mt-Sirt. Using synthetic substrates, peptide libraries, and mutational analysis, we showed that Mt-Sirt exhibits strong selectivity for peptide substrates containing Nε-succinyl-lysine and long-chain fatty-acyl-lysine groups. Substitution of conserved active-site residues (Y53F and R56M) confirmed their roles in substrate recognition and acyl-group discrimination. Inhibition studies revealed that nicotinamide, NADH, ADP-ribose, and mechanism-based thioamide/thiourea analogs inhibited Mt-Sirt activity with low-micromolar to nanomolar potency. Initial-velocity, product-inhibition, and dead-end inhibition analyses confirmed that Mt-Sirt operates by an equilibrium-ordered kinetic mechanism in which NAD+ binds first, followed by the Nε-acylated peptide substrate. We further demonstrated that chemically succinylated Mtb isocitrate lyase 1 (ICL1), a key enzyme in Mtb metabolism, was a substrate of Mt-Sirt in vitro. Lastly, metabolic labeling with tetradec-13-ynoic acid (Alk-12) revealed widespread lysine and N-terminal fatty acylation in Mtb cells, suggesting that Mt-Sirt may regulate previously unrecognized fatty-acyl PTMs in vivo. Together, these findings provide a kinetic and substrate-specificity analysis of Mt-Sirt, and highlight its potential role in controlling reversible lysine acylation in Mtb.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.